Vitamin D Deficiency Clinical Trial
Official title:
The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity
Platelets play pivotal role in atherosclerosis and acute cardiovascular events. Platelet hyperreactivity and increase platelet-monocyte aggregate (PMA) formation are found in HIV infected patients, which may contribute to the excess cardiovascular risk. Low level of vitamin D has been associated with the presence of cardiovascular diseases. The aim of our study is to determine the effect of vitamin D supplementation on platelet activation, platelet reactivity and platelet-leukocyte complex formation in asymptomatic HIV-infected patients treated with ART
1. Study design A prospective intervention study. HIV-infected patients using ART and who
come for follow-up at the Teratai HIV clinic will be asked to participate in the study.
All study participants will receive vitamin D supplementation (soft gel capsule
containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three
consecutive months. The effect on the platelet parameters specified above will be
determined before start cholecalciferol supplementation and after three months.
2. Duration of study Usually, 150 HIV-infected patients are treated with ART every week at
the Teratai HIV clinic of the Hasan Sadikin Hospital Bandung Indonesia. Between half
January 2014 and end of February 2014, 50 patients will be enrolled in this study. We
hypothesize that this period is long enough to include 50 patients for the present
study. Supplementation will take place between March and May and analysis will be done
in June and July. A summary of duration of study is depicted in the study timeline.
3. Study population The study population consists of adult HIV-infected patients treated
with ART enrolled at HIV polyclinic at Hasan Sadikin General Hospital, Bandung,
Indonesia.
4. Sample size calculation Our sample size calculation is based on the primary outcome,
which is the area under the curve (AUC) of the platelet reactivity curve with
P-selectin (CD62P) as platelet activation marker and ADP as platelet agonist. In a
cohort of Dutch HIV-infected patients we found a mean AUC of 2500 with an SD of 660.
Assuming that a decrease in AUC of 2500 to 2100 upon supplementation of vitamin D is
clinically relevant, a sample size of 23 would be sufficient using a paired design with
α 0.05 and a power of 80%.
5. Methods Study parameters/endpoints
There are two study parameters applied in this study:
1. Platelet reactivity, expressed as the membrane expression of the platelet
activation markers CD62P (P-selectin) and fibrinogen binding to integrin αIIbβ3,
to stimulation with increasing concentration of platelet agonists ADP.
2. Platelet-monocyte complexes.
6. Study procedures
a. Enrolment of patients During a scheduled routine polyclinic visit, the treating
internist will identify patients fulfilling inclusion criteria. He/she will explain the
background and objectives of the study to the patient. In case patients opt to
participate, the patient will then be asked to read and undersign the informed consent
form.
Venous blood (three tubes of 3 mL each) will then drawn for study purpose at enrolment
and after three months supplementation for:
1. 25-hydroxyvitamin D level (3 ml serum)
2. Platelet assays as specified above (3 ml CTAD)
3. Full blood count and CD4 cells (3 ml EDTA) In many instances, this will not
require an extra venepuncture as blood is usually collected for planned blood
analysis for routine clinical care during regular polyclinic visits.
Measurements and analysis consist of 25-hydroxyvitamin D level, platelet reactivity,
and platelet-monocyte complexes will be done when the patients participate in the
study. The study participants will receive 180 soft gel cholecalciferol capsules, to be
taken 2 capsules once a day for 90 days as stated above.
As stated above, the second blood analysis will take place three months later after
vitamin D supplementation is completed.
b. Collection of blood samples for vitamin D level analysis As much as 3mL additional
blood is withdrawn while applying venepuncture for routine CD4+ measurement. Collected
blood is stored using red top serum tube without anticoagulant. This will take place at
enrolment (day 0) and after 3 months vitamin D supplementation. Each day of blood
withdrawal, the collected tubes are stored temporarily in wet-iced box prior transfer
to laboratory for vitamin D analysis. At the end of the policlinic day, all tubes are
transferred to the laboratory for serum separation. Then, separated serum is stored so
25-hydroxyvitamin D measurements can be done later. All samples are analysed for
25-hydroxyvitamin D measurements as well as other vitamin D metabolites such as free
25-hydroxyvitamin D measurements. Such analysis can not be done in Indonesia and
therefore samples will be shipped to the Netherlands for this purpose.
c. Collection of blood samples for platelet function analysis As specified under study
parameters above, platelet function analysis can be performed from one 3mL
citrate-anticoagulated blood tube. This will take place at enrolment (day 0) and after
3 months vitamin D supplementation. Each withdrawn blood from the patient, the tube is
directly transferred to the laboratory for platelet function within 30 minutes.
d. Full blood count and CD4 cell measurements These measurements are part of routine
care and will be done in the routine haematological laboratory using 3 ml EDTA blood.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 |